Legal Issues and BPCI Acts

The Patient Protection and Affordable Care Act (PPAC Act) was signed into law in March 2010 in addition to the amendments in the Public Health Service Act (PHS Act) to create an abbreviated approval pathway for biosimilars and follow on biologics.  These new statutory provisions are often referred as the Biologics Price Competition and Innovation Act of 2009 (BPCI Act). This track concentrates upon such legal bindings and the aspects of the BPCI Act that pertain to the biosimilars and biologics. This session on legal issues shall be very beneficial to research scientists from both academic backgrounds and also those from industry R&D.

 

  • Implementation of the BPCI Act
  • Patent protection and infringement issues
  • Patent negotiation and litigation phase
  • Market exclusivities
  • Patent protection and infringement issues
  • Patent negotiation and litigation phase

Related Conference of Legal Issues and BPCI Acts

February 24-25, 2025

2nd International Conference on Pharmacognosy

Madrid, Spain
February 27-28, 2025

8th International on Pharmacy and Pharmaceutical Conference

Prague, Czech Republic
March 10-11, 2025

35th Annual European Pharma Congress

Rome, Italy
April 14-15, 2025

18th European Biosimilars Congress

Paris, France
April 24-25, 2025

18th World Drug Delivery Summit

London, UK
May 05-06, 2025

19th World Drug Delivery Summit

Vancouver, Canada
June 16-17, 2025

3rd Global Online Summit on Nanoscience and Nanotechnology

Zurich, Switzerland
June 23-24, 2025

38th World Congress on Pharmacology

Aix-en-Provence, France
September 23-24, 2025

10th International Conference on Future Pharma and Innovations

Amsterdam, Netherlands
November 27-28, 2025

4th World Conference on Pharma Industry and Medical Devices

Zurich, Switzerland
November 27-28, 2025

4th World Congress on Precision and Personalized Medicine

Zurich, Switzerland

Legal Issues and BPCI Acts Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in